Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Interest & Investment Income (2019 - 2026)

Atea Pharmaceuticals' Interest & Investment Income history spans 8 years, with the latest figure at $2.6 million for Q1 2026.

  • Quarterly Interest & Investment Income fell 47.35% to $2.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.0 million through Mar 2026, down 40.57% year-over-year, with the annual reading at $16.4 million for FY2025, 35.76% down from the prior year.
  • Interest & Investment Income came in at $2.6 million for Q1 2026, down from $3.3 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.9 million in Q3 2023 to a low of $98000.0 in Q1 2022.
  • The 5-year median for Interest & Investment Income is $5.6 million (2022), against an average of $5.0 million.
  • Year-over-year, Interest & Investment Income soared 10862.75% in 2022 and then plummeted 47.35% in 2026.
  • Atea Pharmaceuticals' Interest & Investment Income stood at $5.6 million in 2022, then skyrocketed by 38.76% to $7.8 million in 2023, then dropped by 26.42% to $5.7 million in 2024, then plummeted by 42.2% to $3.3 million in 2025, then decreased by 20.64% to $2.6 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Interest & Investment Income are $2.6 million (Q1 2026), $3.3 million (Q4 2025), and $3.7 million (Q3 2025).